IQVIA Holdings Inc. — Q1 2023 Form 10-Q
Business context and reporting period
Quarter ended March 31, 2023; figures are unaudited and in U.S. dollars. IQVIA provides analytics, technology solutions and clinical research services to the life sciences industry through Technology & Analytics Solutions (TAS), Research & Development Solutions (R&D), and Contract Sales & Medical Solutions (CSMS).
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $3.652 billion | $3.568 billion | +2.4% reported; +4.7% constant currency |
| Operating income | $471 million | $495 million | -4.8% |
| Operating margin | 12.9% | 13.9% | -1.0 percentage point |
| Net income | $289 million | $325 million | -11.1% |
| Diluted EPS | $1.53 | $1.68 | -8.9% |
| Operating cash flow | $417 million | $508 million | -$91 million |
| Cash and cash equivalents | $1.494 billion | $1.216 billion at Dec. 31, 2022 | +$278 million |
| Total debt principal | $13.222 billion | $12.797 billion at Dec. 31, 2022 | +$425 million |
Cost of revenue was 65.7% of revenue versus 65.1%; SG&A was 14.0% versus 13.7%. Cash used in investing was $222 million, primarily reflecting $164 million of property, equipment and software purchases; cash provided by financing was $87 million. Cash less debt principal was approximately $11.7 billion. Current assets of $5.328 billion were below current liabilities of $6.657 billion. The filing reports $695 million of available borrowing capacity on the senior secured revolver and standby letters of credit at quarter-end; the receivables facility had no revolving loan commitment availability.
Material changes versus the prior comparable period
- Constant-currency revenue increased about 4.7%, while currency effects reduced reported growth to 2.4%.
- R&D revenue rose 4.8% to $2.026 billion and segment profit increased to $428 million from $401 million. TAS revenue was nearly flat at $1.444 billion, while segment profit fell 6.5% to $361 million. CSMS revenue declined 6.7% to $182 million; segment profit was $13 million versus $12 million.
- Operating income and net income fell despite revenue growth. Interest expense rose to $141 million from $86 million, mainly due to higher base rates on floating-rate debt and higher net debt. SG&A and restructuring costs also increased; restructuring expense was $17 million versus $7 million.
- Operating cash flow declined, primarily reflecting changes in unearned income and receivables/unbilled services and lower cash-related net income. Investing cash outflow was substantially lower than last year, principally because business acquisition spending fell to $18 million from $430 million.
Outlook, risks and unusual items
- No specific consolidated revenue or earnings guidance is stated in the provided filing text. Management believes available cash, operating cash flows and access to credit facilities will fund operating needs, capital expenditures, contractual obligations and debt service for at least the next 12 months.
- R&D contracted backlog was $27.9 billion at March 31, 2023, up from $27.2 billion at year-end; IQVIA expects approximately $7.3 billion to convert to revenue over the next 12 months. Remaining performance obligations were approximately $31.4 billion; about 30% is expected to be recognized within 12 months and 80% within five years. These measures are not identical: the RPO disclosure excludes certain cancellable, wholly unperformed contracts.
- Restructuring actions to streamline operations and address overcapacity are expected to continue into 2024; most of the $29 million quarter-end restructuring accrual is expected to be paid in 2023 and 2024.
- On April 17, 2023, after quarter-end, IQVIA increased revolving credit facility capacity by $500 million to $2.0 billion and amended specified U.S. dollar benchmark rates from LIBOR to SOFR plus a 10-basis-point credit spread adjustment.
- Key disclosed risks include short-notice termination of many customer contracts, backlog conversion, privacy and data-use restrictions, cybersecurity, foreign exchange, inflation and interest rates, acquisitions and integration, and changing regulation. The company reported material covenant compliance at quarter-end.
- Legal matters include ongoing South Korean privacy-related proceedings and litigation with Veeva, including Veeva counterclaims seeking damages in excess of $200 million. Management does not expect pending proceedings, individually or in aggregate, to have a material adverse effect, but says an unfavorable outcome could materially affect the period resolved.
Important facts for investors to verify
- Whether constant-currency growth, particularly R&D clinical-services growth, is sustained as COVID-19-related work declines.
- Whether operating margins and cash conversion recover given higher operating costs, interest expense and working-capital movements.
- Debt maturity and refinancing exposure: $1.893 billion of contractual principal maturities in 2024 and $2.708 billion in 2025; floating-rate debt creates sensitivity to interest rates.
- Backlog and remaining-performance-obligation conversion assumptions, and the effect of cancellations, project timing and milestone-based billing.
- Developments in the Veeva and South Korean proceedings, and potential cash requirements from litigation, contingent consideration and restructuring.